Armata Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 1996
Net Income	-69.05	-36.92	-23.16	-22.18	-19.48	Upgrade
Depreciation & Amortization	0.97	0.89	1.17	1.11	1.35	Upgrade
Share-Based Compensation	0.94	3.11	2.88	3.48	4.27	Upgrade
Other Operating Activities	19.71	0.44	-4.47	-0.68	-1.73	Upgrade
Operating Cash Flow	-47.42	-32.48	-23.58	-18.27	-15.58	Upgrade
Capital Expenditures	-8.13	-2.21	-1.3	-0.82	-0.13	Upgrade
Acquisitions	0	0	0	0	3.01	Upgrade
Investing Cash Flow	-8.13	-2.21	-1.3	-0.82	2.88	Upgrade
Share Issuance / Repurchase	0.01	44.52	26.93	23.06	9.98	Upgrade
Debt Issued / Paid	54.03	0	0	0.72	0	Upgrade
Other Financing Activities	-0.04	-0.5	-1.41	-0.57	-1	Upgrade
Financing Cash Flow	53.99	44.02	25.52	23.21	8.98	Upgrade
Net Cash Flow	-1.57	9.32	0.64	4.12	-3.73	Upgrade
Free Cash Flow	-55.56	-34.69	-24.88	-19.09	-15.71	Upgrade
Free Cash Flow Margin	-1226.69%	-629.85%	-556.08%	-2320.05%	-	Upgrade
Free Cash Flow Per Share	-1.54	-1.01	-1.03	-1.16	-2.01	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).